ClinicalTrials.gg
CompletedNCT04512170Updated Mar 15, 2022

Single and Multiple Dose Safety, Tolerability, PK and Food Effect Study of HEC585 in Healthy Male and Female Subjects

A Phase 1 interventional study of HEC585 and placebo in Idiopathic Pulmonary Fibrosis, sponsored by Sunshine Lake Pharma Co., Ltd.. Completed at 1 site in China. Open to participants aged 18 Years to 45 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2022-03-15.

Sponsored by Sunshine Lake Pharma Co., Ltd. · Phase 1, Interventional, and Treatment

From the registry’s dates

  • Primary completion was Aug 2021, 5 years 2 months ago, and no results have been posted to the registry.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
72
Allocation
Randomized
Ages
18 Years to 45 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 67 studies in Idiopathic Pulmonary Fibrosis with a site in China — 25 open to participants now, 29 under way, 8 of them phase 3. Idiopathic Pulmonary Fibrosis · China.

Enrollment
33rd of 60
72 · median 83
Started
2020
with 5 others
Phase 1
20 of 67
5 open now
Registered
14th of 67
by date
Lead sponsor
5 of 67
Sunshine Lake Pharma Co., Ltd.

Among the 67 studies in Idiopathic Pulmonary Fibrosis with a site in China, this one is the 33rd largest by enrollment of the 60 interventional ones that give a count, is one of 6 that started in 2020, is one of 20 in phase 1, and was the 14th registered.

Idiopathic Pulmonary Fibrosis

577 studies on the registry are indexed under Idiopathic Pulmonary Fibrosis; 124 are open to participants now.

Browse Idiopathic Pulmonary Fibrosis studies →

Open to participants now

25 of the 67 studies in Idiopathic Pulmonary Fibrosis with a site in China are open now. Recruiting first, the newest first:

20 more — sign in →

All 25 open studies →

A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →

Who these studies take

Of the 86 Idiopathic Pulmonary Fibrosis studies recruiting now, 56 (65%) set no upper age limit and 8 (9%) stop at 75 or younger; 3 take children under 18; 15 take healthy volunteers.

This study: 18 Years to 45 Years · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 67 studies in Idiopathic Pulmonary Fibrosis with a site in China, or all of them as a file.
02

Study summary

The Safety, Tolerability Pharmacokinetic and Food Effect Study of HEC585 in Healthy Male and Female Subjects

03

Conditions studied

  • Idiopathic Pulmonary Fibrosis
04

Who can participate

Ages eligible
18 Years to 45 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Subjects who are willing and are able to provide a written to participate in the study.
  2. Without Plann for pregnancy or pregnant within 3 months after enrollment throughout the trial.
  3. Subjects aged between 18 and 45 (both inclusive) years old.
  4. Healthy volunteers has a body weight ≥50 kg (for male) or ≥ 45kg (for female) and ≥19 and ≤28 kg/m2 at screening.
  5. Subjects, who are healthy, as having no abnormalities in vital signs, physical examination, clinical laboratory test results, Chest X-ray and 12-lead (ECG).

Exclusion criteria

Exclusion Criteria:

  1. Subjects with a positive serology for (HIV) antibodies, surface antigen (HBsAg), virus (HCV) antibodies and/or TP antibodies at screening.
  2. Subjects suffering from gastrointestinal diseases that can interfere with absorption or metabolism of drugs within 6 months before screening; and/or with history of central nervous system, cardiovascular system, digestive system, respiratory system, urinary system, blood system, immune system (such as thymus disease), reproductive system (such as prostate, testis, epididymis, ovarian disease); and/or thyroid disease or previous thyroid surgery, malignant tumor, metabolic disorder or others medical conditions (such as history of mental illness, etc.) that are not suitable for clinical trial participation.
  3. Known allergic reactions or to any of the drug formulation(s), anaphylaxis physique.
  4. Use of any prescription or non-prescription medications within 14 days prior to initial dosing,Use of any medications known to inhibit or induce cytochrome P enzyme drug metabolism within 28 days prior to initial dosing.
  5. Consume foods or beverages containing caffeine, xanthine, alcohol, and grapefruit within 48 hours prior to initial dosing.
  6. Positive results from urine drug screen test.
  7. History of alcoholism or drink regularly within 3 months prior to the study(defined as Alcohol consumption of > 21 units/week), or positive results from alcohol breath test.
  8. Regular smoking of more than 10 cigarettes per day within 3 months before administration of study drug, or inability to refrain from smoking during the course of the study.
  9. Donate blood or lose blood 400 mL or more within 1 month prior to initial dosing.
  10. Subjects who plan to receive or have had organ transplants.
  11. Females who are lactating/breastfeeding, or positive result from pregnancy test for women of .
  12. Subjects who participated in another clinical trial within 3 months prior to initial dosing.
  13. Any other condition with in the opinion of the investigator would render the patient unsuitable for inclusion in the study.
Terms in these criteria, in plain language(10)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
72 participants (actual)

Study arms

  • Experimental
    A single dose HEC585(pilot trial arm)

    Healthy subjects receive a single dose of HEC585

    Drug: HEC585

  • Experimental
    Single and Mulltiple doses HEC585( Part 1, Cohort 1)

    Healthy subjects receive Single and multiple doses of HEC585 or matching placebo

    Drug: HEC585 · Drug: placebo

  • Experimental
    Single and Mulltiple doses HEC585( Part 1, Cohort 2)

    Healthy subjects receive Single and multiple doses of HEC585 or matching placebo

    Drug: HEC585 · Drug: placebo

  • Experimental
    Single and Mulltiple doses HEC585( Part 1, Cohort 3)

    Healthy subjects receive Single and multiple doses of HEC585 or matching placebo

    Drug: HEC585 · Drug: placebo

  • Experimental
    Single dose of HEC585 (Part 2,Fed/Fasting)

    Following an overnight fast of at least 10 hours, a single dose of HEC585 will be administered on 2 separate occasions (fasting and after meal) in a randomized crossover fashion with different food restrictions.

    Drug: HEC585 · Drug: placebo

  • Experimental
    two-period study at 400 mg dose group (part 3,Fed)

    Healthy subjects receive Single/multiple doses of HEC585 or matching placebo in two cycles.

    Drug: HEC585 · Drug: placebo

Interventions

  • DrugHEC585

    single or Mulltiple doses up to 10 days

  • Drugplacebo

    single or Mulltiple doses up to 10 days

06

What researchers measure

Primary outcomes

  1. Safety and Tolerability of HEC585 by Assessment of the Number of Adverse Events (AEs) Following Administration of Oral Solution in Single Ascending Dose and Multiple Ascending Doses

    To investigate the safety and tolerability of HEC585 by assessment of AEs (non-serious and serious) following administration of oral solution in SAD and MAD

    Time frame: up to 18 days

Secondary outcomes

  1. PK parameters - AUC0-∞

    area under the concentration versus time curve (AUC) from time zero to infinity

    Time frame: up to 96 hours

  2. PK parameters - Cmax

    Geometric Mean of Maximum Observed Plasma Concentration of HEC585

    Time frame: up to 96 hours

  3. PK parameters -tmax

    maximum observed plasma concentration

    Time frame: up to 96 hours

  4. PK parameters -t½

    apparent terminal elimination half-life

    Time frame: up to 96 hours

  5. PK parameters -Vz/F

    apparent volume of distribution

    Time frame: up to 96 hours

  6. PK parameters - MRT

    the Mean Residence Time

    Time frame: up to 96 hours

  7. PK parameters -CL/F

    the Apparent Clearance

    Time frame: up to 96 hours

  8. PK parameters -R

    the Accumulation Ratio

    Time frame: up to 96 hours

  9. Food Effect

    Effect of Food on PK parameters of HEC585

    Time frame: up to 96 hours

07

Study locations

1 site
  • Shanghai Xuhui Central Hospital
    Shanghai, China
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Jul 2020 to primary completion in Aug 2021, 13 months.

Of 60 industry-sponsored phase 1 interventional studies under Idiopathic Pulmonary Fibrosis, half reached primary completion within 10 months of starting (the median), counting those still running; a quarter within 5 and three quarters within 16. This study's 13 months is above that.

Counting every sponsor, half of 75 studies reached it within 12 months; a quarter within 5 and three quarters within 23.

How these figures are worked out, and which studies are left out of them.

Registered
Aug 7, 2020
First posted
Aug 13, 2020
StartActual
Jul 13, 2020
Primary completionActual
Aug 23, 2021
CompletionActual
Aug 23, 2021
Last update
Mar 15, 2022
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Mar 15, 2022, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT04512170
Responsible party
Sponsor
First posted
Aug 13, 2020
Start date
Jul 13, 2020
Primary completion
Aug 23, 2021
Completion
Aug 23, 2021
Last update
Mar 15, 2022

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Mar 2022. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Yinfenidone

Start the discussion